Earlier this fall, Given Imaging faced down restive shareholder Discovery Group, which urged the Israeli maker of the PillCam endoscopic camera to explore a sale. Now that Covidien will snatch up the company for $860 million, the activist investor has decided to move on.
U.K. CRO Quotient Clinical is now the property of private equity outfit Bridgepoint Development Capital, joining the crowd of pharma contractors signing up to be acquired in a fast-consolidating industry.
It seems the bankrupt Savient has found a savior in Crealta Pharmaceuticals. The biotech has agreed to sell itself and its assets, including leading product Krystexxa, to Crealta for $120.4 million, and the companies will seek court approval for the sale later this week.
CareFusion has its eye on an Israeli infusion pump maker and will invest $100 million in the company's operations, the San Diego med tech company's second big deal in the last month.
For Carl Icahn and his allies, acquiring 12.6% of Hologic shares gave them enough leverage to start getting their way. As part of an agreement with Icahn, the company added two new independent directors and replaced its CEO.
Irish medical device giant Covidien over the weekend announced a definitive agreement to acquire PillCam maker Given Imaging for $860 million, ending about a year of takeover talk.
European CRO Venn Life Sciences is back at the buyer's table, picking up Ireland's Medevol in a deal worth just over $1 million.
CRO Sarah Cannon Research Institute has acquired Connecticut's Clinical Development Group, a trial consulting outfit with a wide range of offerings in oncology R&D.
Federal agents reportedly carried boxes of documents out of the Reckitt Benckiser headquarters in Virginia on Tuesday. The officials did not disclose the purpose of the warrant.
When Thermo Fisher Scientific announced a $3.2 billion bond offering Wednesday, Fitch Ratings promptly lowered the medical device maker's credit rating to BBB and Moody's Investors Service said it likely will do the same.